Drug Profile
Research programme: antibacterials - Biophage/Nymox
Latest Information Update: 14 Feb 2008
Price :
$50
*
At a glance
- Originator Biophage Pharma; Nymox Pharmaceutical Corporation
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 02 May 2006 No development reported - Preclinical for Bacterial infections in Canada (unspecified route)
- 25 Jan 2001 Preclinical development for Bacterial infections in Canada (Unknown route)